Aduro Biotech, Inc.
740 Heinz Avenue
Berkeley, California 94710
August 24, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Re: | Aduro Biotech, Inc. Registration Statement on Form S-4 (File No. 333-239989) | |||
Request for Acceleration of Effectiveness | ||||
Requested Date: August 26, 2020 | ||||
Requested Time: 9:00 a.m. Eastern Time | ||||
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Aduro Biotech, Inc. (the “Registrant”) hereby requests acceleration of the effective date of the Registration Statement on Form S-4 (File No. 333-239989), as amended (the “Registration Statement”), so that it may become effective at 9:00 a.m. Eastern Time on August 26, 2020, or as soon as possible thereafter. The Registrant hereby authorizes Luke Bergstrom and/or Kathleen Wells, of Latham & Watkins LLP, to orally modify or withdraw this request for acceleration.
Thank you for your assistance. We request that we be notified of such effectiveness by a telephone call to Kathleen Wells at (650) 463-2677, or in her absence, Luke Bergstrom, of Latham & Watkins LLP, at (650) 463-3083. We also respectfully request that a copy of the written order from the Commission verifying the effective time and date of such Registration Statement be sent to Latham & Watkins LLP, attention: Kathleen Wells, via facsimile at (650) 463-2600.
Very truly yours, |
Aduro Biotech, Inc. |
| /s/ Stephen T. Isaacs |
Stephen T. Isaacs |
President and Chief Executive Officer |
| cc: | Stephen T. Isaacs, Aduro Biotech, Inc. | |
| Celeste Ferber, Aduro Biotech, Inc. | ||
| William G. Kachioff, Aduro Biotech, Inc. | ||
| Eric Dobmeier, Chinook Therapeutics U.S., Inc. | ||
| Kirk Schumacher, Chinook Therapeutics U.S., Inc. | ||
| Luke Bergstrom, Latham & Watkins LLP | ||
| Amanda L. Rose, Fenwick & West LLP | ||
| Ryan Mitteness, Fenwick & West LLP |
